Acadia Pharmaceuticals | ACAD - Себестоимость





Себестоимость Изменить Дата
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
ALKERMES USD 46.21M 5.38M 2025-12
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
Biogen USD 797.5M 302M 2026-03
BioMarin Pharmaceutical USD 161.56M 16.62M 2025-12
Bristol-Myers Squibb USD 4.92B 657M 2025-12
Cara Therapeutics USD 0 0 2025-03
Corcept Therapeutics USD 2.54M 2.05M 2025-12
Cytokinetics USD 99.23M 13.32M 2025-09
Eisai JPY 51.08B 5.56B 2025-12
Eli Lilly USD 3.37B 363.7M 2025-12
Incyte USD 121.18M 22.18M 2025-12
J&J USD 8.07B 103M 2026-03
Moderna USD 452M 245M 2025-12
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Pfizer USD 6.29B 2.12B 2025-12
Prothena USD 28.94M 11.58M 2025-09
PTC Therapeutics USD 16.3M 7.02M 2025-12
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
Ultragenyx Pharmaceutical USD 29M 1.01M 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Vertex Pharmaceuticals USD 466M 51.2M 2025-12